Treatment-Induced Neuropathy of Diabetes
Purpose of Review
Treatment-induced neuropathy of diabetes (TIND) is an under-recognized iatrogenic painful sensory and autonomic neuropathy. This review highlights the clinical symptoms and signs, raises awareness of the cause, and provides education about prevention of TIND.
TIND may be triggered by a rapid decline in the blood glucose levels following the use of insulin, oral hypoglycemic medications, or even diet only to control diabetes. This may be seen in up to 10% of patients with diabetic neuropathy and has the potential for significant long-term complications that could be avoided through careful disease management. Based on the available evidence, a decrease in the glycosylated hemoglobin A1C of more than 3 points in 3 months in individuals with chronic hyperglycemia increases the risk of developing TIND.
TIND is more common than previously suspected, and is tied to rates of glycemic control. Slower changes to glucose control are suggested, although there is no prospective data on disease prevention. Future research is necessary to guide treatment recommendations.
KeywordsNeuropathy Diabetes Complications Treatment
Compliance with Ethical Standards
Conflict of Interest
Christopher H. Gibbons has received research funding from Celgene and Grifols, and has served on advisory boards for Lundbeck and Pfizer, and served on data safety monitoring boards of Janssen and Astellas.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Caravati CM. Insulin neuritis: a case report. VaMedMonthly. 1933;59:745–6.Google Scholar
- 2.Kihara M, Zollman PJ, Smithson IL, Lagerlund TD, Low PA. Hypoxic effect of exogenous insulin on normal and diabetic peripheral nerve. AmJPhysiol. 1994;266(6 Pt 1):E980–E5.Google Scholar
- 6.Gade GN, Hofeldt FD, Treece GL. Diabetic neuropathic cachexia. Beneficial response to combination therapy with amitriptyline and fluphenazine. JAMA 1980;243(11):1160–1.Google Scholar
- 7.Massey EW. Diabetic neuropathic cachexia and diabetic amyotrophy. Acta DiabetolLat. 1982;19(1):91–5.Google Scholar
- 8.Blau RH. Diabetic neuropathic cachexia. Report of a woman with this syndrome and review of the literature. ArchInternMed. 1983;143(10):2011–2.Google Scholar
- 13.•• Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138(Pt 1):43–52. This is the first study describing the frequency of TIND in a referral population. This paper also links the rate of change in the HbA1C with the risk of complciations CrossRefPubMedGoogle Scholar
- 14.CDC. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. In: CDC, editor.: Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.Google Scholar
- 16.• Colton PA, Olmsted MP, Daneman D, Farquhar JC, Wong H, Muskat S, et al. Eating disorders in girls and women with type 1 diabetes: a longitudinal study of prevalence, onset, remission, and recurrence. Diabetes Care. 2015;38(7):1212–7. An important publication on the frequency and relapse rates of eating disorders in diabetes CrossRefPubMedGoogle Scholar
- 19.Takii M, Uchigata Y, Tokunaga S, Amemiya N, Kinukawa N, Nozaki T, et al. The duration of severe insulin omission is the factor most closely associated with the microvascular complications of type 1 diabetic females with clinical eating disorders. IntJEatDisord. 2008;41(3):259–64.Google Scholar
- 24.Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. CurrDiabRep. 2010;10(4):276–82.Google Scholar
- 26.Davis MD, Beck RW, Home PD, Sandow J, Ferris FL. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH insulin. ExpClinEndocrinolDiabetes. 2007;115(4):240–3.Google Scholar
- 27.Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33(5):1090–6.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Pop-Busui R, Low PA, Waberski BH, Martin CL, Albers JW, Feldman EL, et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation. 2009;119(22):2886–93.CrossRefPubMedPubMedCentralGoogle Scholar